Dermapharm Holding SE (DMP) - Total Assets
Based on the latest financial reports, Dermapharm Holding SE (DMP) holds total assets worth €2.27 Billion EUR (≈ $2.66 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore DMP operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Dermapharm Holding SE - Total Assets Trend (2013–2025)
This chart illustrates how Dermapharm Holding SE's total assets have evolved over time, based on quarterly financial data. See net assets of Dermapharm Holding SE for net asset value and shareholders' equity analysis.
Dermapharm Holding SE - Asset Composition Analysis
Current Asset Composition (December 2025)
Dermapharm Holding SE's total assets of €2.27 Billion consist of 31.9% current assets and 68.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 9.2% |
| Accounts Receivable | €121.38 Million | 5.5% |
| Inventory | €328.71 Million | 14.9% |
| Property, Plant & Equipment | €318.54 Million | 14.5% |
| Intangible Assets | €480.44 Million | 21.8% |
| Goodwill | €587.06 Million | 26.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how Dermapharm Holding SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Dermapharm Holding SE.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dermapharm Holding SE's current assets represent 31.9% of total assets in 2025, a decrease from 52.0% in 2013.
- Cash Position: Cash and equivalents constituted 9.2% of total assets in 2025, up from 1.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 27.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 26.6% of total assets.
Dermapharm Holding SE Competitors by Total Assets
Key competitors of Dermapharm Holding SE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
China | CN¥7.80 Billion |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
|
China | CN¥6.56 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Dermapharm Holding SE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.00 | 2.05 | 2.69 |
| Quick Ratio | 1.08 | 0.91 | 1.23 |
| Cash Ratio | 0.00 | 0.00 | 0.64 |
| Working Capital | €389.81 Million | €323.50 Million | €268.12 Million |
Dermapharm Holding SE - Advanced Valuation Insights
This section examines the relationship between Dermapharm Holding SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.13 |
| Latest Market Cap to Assets Ratio | 1.02 |
| Asset Growth Rate (YoY) | 6.0% |
| Total Assets | €2.20 Billion |
| Market Capitalization | $2.26 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Dermapharm Holding SE's assets above their book value (1.02x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Dermapharm Holding SE's assets grew by 6.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Dermapharm Holding SE (2013–2025)
The table below shows the annual total assets of Dermapharm Holding SE from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.20 Billion ≈ $2.58 Billion |
+6.00% |
| 2024-12-31 | €2.08 Billion ≈ $2.43 Billion |
-3.73% |
| 2023-12-31 | €2.16 Billion ≈ $2.53 Billion |
+52.93% |
| 2022-12-31 | €1.41 Billion ≈ $1.65 Billion |
+0.42% |
| 2021-12-31 | €1.41 Billion ≈ $1.64 Billion |
+14.91% |
| 2020-12-31 | €1.22 Billion ≈ $1.43 Billion |
+17.18% |
| 2019-12-31 | €1.04 Billion ≈ $1.22 Billion |
+48.30% |
| 2018-12-31 | €704.58 Million ≈ $823.73 Million |
+69.65% |
| 2017-12-31 | €415.30 Million ≈ $485.53 Million |
+33.24% |
| 2016-12-31 | €311.70 Million ≈ $364.41 Million |
+5.07% |
| 2015-12-31 | €296.67 Million ≈ $346.83 Million |
-10.26% |
| 2014-12-31 | €330.60 Million ≈ $386.50 Million |
-5.54% |
| 2013-12-31 | €349.98 Million ≈ $409.16 Million |
-- |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers br… Read more